Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial

Michael Manns; Didier Samuel; Edward J Gane; David Mutimer; Geoff McCaughan; Maria Buti; Martín Prieto; José Luis Calleja; Markus Peck-Radosavljevic; Beat Müllhaupt; Kosh Agarwal; Peter Angus; Eric M Yoshida; Massimo Colombo; Mario Rizzetto; Hadas Dvory-Sobol; Jill Denning; Sarah Arterburn; Phillip S Pang; Diana Brainard; John G McHutchison; Jean-François Dufour; Hans Van Vlierberghe; Bart van Hoek; Xavier Forns

doi:10.1016/s1473-3099(16)00052-9

Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial

The Lancet Infectious Diseases ◽

10.1016/s1473-3099(16)00052-9 ◽

2016 ◽

Vol 16 (6) ◽

pp. 685-697 ◽

Cited By ~ 300

Author(s):

Michael Manns ◽

Didier Samuel ◽

Edward J Gane ◽

David Mutimer ◽

Geoff McCaughan ◽

...

Keyword(s):

Hepatitis C Virus ◽

Liver Disease ◽

Hepatitis C ◽

Virus Infection ◽

Phase 2 ◽

Hepatitis C Virus Infection ◽

Genotype 1 ◽

Open Label ◽

Advanced Liver Disease ◽

Phase 2 Trial

Download Full-text

Faculty Opinions recommendation of Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726172820.793515335 ◽

2016 ◽

Author(s):

Philip Rosenthal

Keyword(s):

Hepatitis C Virus ◽

Liver Disease ◽

Hepatitis C ◽

Virus Infection ◽

Phase 2 ◽

Hepatitis C Virus Infection ◽

Genotype 1 ◽

Open Label ◽

Advanced Liver Disease ◽

Phase 2 Trial

Download Full-text

Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial

Gastroenterology ◽

10.1053/j.gastro.2016.07.039 ◽

2016 ◽

Vol 151 (5) ◽

pp. 893-901.e1 ◽

Cited By ~ 38

Author(s):

Eric Lawitz ◽

Nancy Reau ◽

Federico Hinestrosa ◽

Mordechai Rabinovitz ◽

Eugene Schiff ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Virus Infection ◽

Phase 2 ◽

Hepatitis C Virus Infection ◽

Genotype 1 ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase

Download Full-text

Faculty Opinions recommendation of Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726606111.793521809 ◽

2016 ◽

Author(s):

Philip Rosenthal

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Virus Infection ◽

Phase 2 ◽

Hepatitis C Virus Infection ◽

Genotype 1 ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase

Download Full-text

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

The Lancet ◽

10.1016/s0140-6736(14)61795-5 ◽

2015 ◽

Vol 385 (9973) ◽

pp. 1075-1086 ◽

Cited By ~ 208

Author(s):

Eric Lawitz ◽

Edward Gane ◽

Brian Pearlman ◽

Edward Tam ◽

Wayne Ghesquiere ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Phase 2 ◽

Efficacy And Safety ◽

Genotype 1 ◽

Virus Genotype ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase ◽

Null Response

Download Full-text

P0759 : Hepatitis C virus infection selectively affects “executive functions” in patients with chronic non advanced liver disease

Journal of Hepatology ◽

10.1016/s0168-8278(15)30962-4 ◽

2015 ◽

Vol 62 ◽

pp. S613-S614

Author(s):

A. Rocco ◽

D. Angrisani ◽

M. Sanduzzi Zamparelli ◽

V. Occhipinti ◽

D. Compare ◽

...

Keyword(s):

Hepatitis C Virus ◽

Liver Disease ◽

Hepatitis C ◽

Virus Infection ◽

Executive Functions ◽

Hepatitis C Virus Infection ◽

Advanced Liver Disease

Download Full-text

Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial

The Lancet ◽

10.1016/s0140-6736(14)61793-1 ◽

2015 ◽

Vol 385 (9973) ◽

pp. 1087-1097 ◽

Cited By ~ 202

Author(s):

Mark Sulkowski ◽

Christophe Hezode ◽

Jan Gerstoft ◽

John M Vierling ◽

Josep Mallolas ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Phase 2 ◽

Efficacy And Safety ◽

Genotype 1 ◽

Virus Genotype ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase

Download Full-text

496 Increased intrahepatic cyclooxygenase-2 and metalloproteinase-2 and -9 expression associates with advanced liver disease in chronic hepatitis C virus infection: Role of viral core and NS5A proteins

Journal of Hepatology ◽

10.1016/s0168-8278(04)90496-5 ◽

2004 ◽

Vol 40 ◽

pp. 146 ◽

Cited By ~ 1

Author(s):

O. Nunez ◽

A. Fernandez-Martinez ◽

A. Apolinario ◽

R. Lorente ◽

L. Bosca ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Liver Disease ◽

Hepatitis C ◽

Virus Infection ◽

Chronic Hepatitis C ◽

Hepatitis C Virus Infection ◽

Advanced Liver Disease ◽

Chronic Hepatitis C Virus

Download Full-text

Faculty Opinions recommendation of Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718020296.793478787 ◽

2013 ◽

Author(s):

Arthur Kim

Keyword(s):

Hepatitis C ◽

Phase 2 ◽

Genotype 1 ◽

Hepatitis C Infection ◽

Open Label ◽

Multicentre Phase ◽

Phase 2 Trial ◽

Treatment Naïve ◽

Peginterferon Alfa ◽

Ns3 Protease

Download Full-text

Faculty of 1000 evaluation for Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718020710.793480337 ◽

2013 ◽

Author(s):

Philip Rosenthal

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Phase 2 ◽

Genotype 1 ◽

Virus Genotype ◽

Double Blind ◽

Phase 2 Trial ◽

Pegylated Interferon Alfa

Download Full-text

Variant in CD209 promoter is associated with severity of liver disease in chronic hepatitis C virus infection

Human Immunology ◽

10.1016/j.humimm.2010.05.007 ◽

2010 ◽

Vol 71 (8) ◽

pp. 829-832 ◽

Cited By ~ 22

Author(s):

Elizabeth J. Ryan ◽

Megan Dring ◽

Cliona M. Ryan ◽

Carol McNulty ◽

Nigel J. Stevenson ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Liver Disease ◽

Hepatitis C ◽

Virus Infection ◽

Chronic Hepatitis C ◽

Hepatitis C Virus Infection ◽

Chronic Hepatitis C Virus

Download Full-text